




RealRate

PHARMACEUTICAL 2022

Statera Biopharma Inc
Rank 467 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Statera Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Statera Biopharma Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 16% points. The greatest weakness of Statera Biopharma Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 155% points.

The company's Economic Capital Ratio, given in the ranking table, is 22%, being 253% points below the market average of 275%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	4,147	Assets	21,170
Cost of Goods Sold	488	Liabilities	22,676
Intangible Assets	10,848	Expenses	99,831
Liabilities, Current	11,245	Revenues	1,487
Liabilities, Non-Current	806	Stockholders Equity	-1,507
Other Assets	5,972	Net Income	-101,875
Other Compr. Net Income	18	Comprehensive Net Income	-101,866
Other Expenses	67,680	BaseVar	74,357
Other Liabilities	10,625	ECR before LimitedLiability	-480%
Other Net Income	-3,531	Economic Capital Ratio	22%
Other Revenues	1,487		
Property and Equipment	202		
Research and Development	11,830		
Selling, General and Administrative Expense	19,832		